These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12805322)

  • 1. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
    Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
    J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
    Kuball J; Wen SF; Leissner J; Atkins D; Meinhardt P; Quijano E; Engler H; Hutchins B; Maneval DC; Grace MJ; Fritz MA; Störkel S; Thüroff JW; Huber C; Schuler M
    J Clin Oncol; 2002 Feb; 20(4):957-65. PubMed ID: 11844817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
    Fujiwara T; Tanaka N; Kanazawa S; Ohtani S; Saijo Y; Nukiwa T; Yoshimura K; Sato T; Eto Y; Chada S; Nakamura H; Kato H
    J Clin Oncol; 2006 Apr; 24(11):1689-99. PubMed ID: 16505415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
    Zhang S; Li Y; Li L; Zhang Y; Gao N; Zhang Z; Zhao H
    J Oral Maxillofac Surg; 2009 May; 67(5):1074-82. PubMed ID: 19375021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
    Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
    Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
    Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
    Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
    Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
    J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S; Karlsson MG
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy: the challenges of translating laboratory research into clinical practice.
    Connell PP; Weichselbaum RR
    J Clin Oncol; 2003 Jun; 21(12):2230-1. PubMed ID: 12805319
    [No Abstract]   [Full Text] [Related]  

  • 15. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells.
    Ruifa H; Liwei L; Binxin L; Ximing L
    Urol Int; 2006; 77(4):355-61. PubMed ID: 17135787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.